Month: February 2024

MGP Ingredients Reports Strong Fourth Quarter and Full Year 2023 Results

Written by Customer Service on February 22, 2024. Posted in Public Companies.

Record full year gross profit increased 20% from prior year period ATCHISON, Kan., Feb. 22, 2024 (GLOBE NEWSWIRE) — MGP Ingredients, Inc. (Nasdaq:MGPI), a leading provider of distilled spirits, branded spirits, and food ingredient solutions, today reported results for the fourth quarter and full year ended December 31, 2023. 2023 fourth quarter consolidated results compared to 2022 fourth quarterSales increased 13% to $214.9 million. Gross profit increased 35% to $85.1 million, representing 39.6% of sales. Operating income increased 45% to $43.1 million. Adjusted operating income increased 70% to $50.4 million. Net income increased 38% to $31.0 million. Adjusted net income increased 63% to $36.6 million. Adjusted EBITDA increased 60% to $56.2 million. Basic earnings per common share (“EPS”) increased to $1.39 per...

AGF Investments Announces February 2024 Cash Distributions for AGF Enhanced U.S. Equity Income Fund and AGF Systematic Global Infrastructure ETF

Written by Customer Service on February 22, 2024. Posted in Dividend Reports And Estimates.

TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) today announced the February 2024 cash distributions for *AGF Enhanced U.S. Equity Income Fund and AGF Systematic Global Infrastructure ETF, which pay monthly distributions. Unitholders of record on March 1, 2024 will receive cash distributions payable on March 7, 2024. Details regarding the final “per unit” distribution amounts are as follows:ETF Ticker Exchange Cash Distribution Per Unit ($)AGF Enhanced U.S. Equity Income Fund* AENU Cboe Canada Inc. $0.124413AGF Systematic Global Infrastructure ETF QIF Cboe Canada Inc. $0.119261*AGF Enhanced U.S. Equity Income Fund is a mutual fund with an ETF series option. Further information about the AGF ETFs can be found at AGF.com. This information is not intended to provide legal, accounting,...

Form 8.3 – [ LXi REIT PLC – 21 02 2024] – (CGWL)

Written by Customer Service on February 22, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LXi REIT PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Cosmin Pitigoi to Join Flywire as Chief Financial Officer

Written by Customer Service on February 22, 2024. Posted in Public Companies.

Former PayPal senior finance executive brings decades of experience and leadership across global payments, pricing, treasury, finance and investor relations BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) — Flywire Corporation (Nasdaq: FLYW) (Flywire), a global payments enablement and software company, today is announcing Cosmin Pitigoi will join the Company as Chief Financial Officer, beginning March 4, 2024. Pitigoi will report to Flywire CEO Mike Massaro and will oversee Flywire’s accounting, financial planning and analysis, financial reporting, investor relations, internal audit, SEC reporting, tax, credit and risk and treasury functions. “Given Flywire’s continued growth, we looked for a financial leader who could help us scale financial operations, optimize costs and improve our global footprint,” said Mike Massaro, CEO of Flywire....

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

Written by Customer Service on February 22, 2024. Posted in Public Companies.

— Fourth quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $24.2 million — — Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in hypothalamic obesity; top-line data on track for 1H2025 — — Announced Phase 3 development plans for setmelanotide in hypothalamic obesity in Japan — — Spain and Italy authorities approve reimbursement for IMCIVREE to treat patients with Bardet-Biedl syndrome – — Acquired global rights to oral MC4R agonist LB54640 from LG Chem — — IND application for RM-718 accepted by the FDA – — Management to host conference call today at 8:00 a.m. ET — BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company...

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Written by Customer Service on February 22, 2024. Posted in Public Companies.

KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 2025 Additional KT-333 (STAT3) and KT-253 (MDM2) Phase 1 data expected in 2024 Well-capitalized with $745 million1 in cash as of January 9, 2024, and runway into the first half of 2027 Company to hold call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided...

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

Written by Customer Service on February 22, 2024. Posted in Public Companies.

DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, February 29, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2023, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 6933453. A live audio webcast of the call will also be available on the Investors’ section of the Company’s website, www.chimerix.com. An archived webcast will be available on the Chimerix...

Glatfelter Reports Fourth Quarter and Year End 2023 Results

Written by Customer Service on February 22, 2024. Posted in Earnings Releases And Operating Results.

~ Q4 performance in-line with expectations despite reduced production to manage inventory levels ~~ Announced plans for Merger with Berry Global’s HHNF business anticipated in second half of 2024 ~ 2023 Fourth Quarter and Year-end Highlights:Generated net sales of $320 million in Q4 and $1.4 billion in 2023; loss from continuing operations of $8.6 million in Q4 and $78.1 million in 2023 Achieved Q4 Adjusted EBITDA of $25 million and full-year EBITDA of $93 million, in-line with Q3 performance and consistent with full year guidance Delivered robust Spunlace performance with $5.7 million Adjusted EBITDA in Q4 and $11.2 million for full year Managed effectively the impact of tornado damage at the Spunlace Tennessee converting operation with minimal disruption to customers; $5 million insurance expense excluded from adjusted earnings Generated...

TransUnion Declares Fourth Quarter 2023 Dividend of $0.105 per Share

Written by Customer Service on February 22, 2024. Posted in Dividend Reports And Estimates.

CHICAGO, Feb. 22, 2024 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today announced that its Board of Directors declared a cash dividend of $0.105 per share for the fourth quarter 2023. The dividend will be payable on March 22, 2024, to shareholders of record on March 7, 2024. About TransUnion (NYSE: TRU) TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As...

Armada Hoffler Reports Fourth Quarter and Full Year 2023 Results

Written by Customer Service on February 22, 2024. Posted in Dividend Reports And Estimates.

Net Loss of $0.27 per Diluted Share for the Fourth Quarterand $0.05 per Diluted Share for the Full Year Normalized FFO of $0.31 per Diluted Share for the Fourth Quarterand $1.24 per Diluted Share for the Full Year Announced 5% Increase in the Quarterly Cash Dividend on Common Stock Dividends Declared During the Year Represent a 7.6% Year-Over-Year Increase Introduced 2024 Full-Year Normalized FFO Guidance Range of $1.21 to $1.27 per Diluted Share VIRGINIA BEACH, Va., Feb. 22, 2024 (GLOBE NEWSWIRE) — Armada Hoffler Properties, Inc. (NYSE: AHH) today announced its results for the quarter and year ended December 31, 2023 and provided an update on current events. Highlights include:Net loss attributable to common stockholders and OP Unitholders of $23.9 million and $4.5 million for the three months and year ended December 31, 2023,...

Month: February 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals